Asia-Pacific Ophthalmology Therapeutics Market was worth $4.89 billion in 2018 and is estimated to grow at a CAGR of 8.5%, to reach $7.35 billion by 2023. Ophthalmology is the branch of medicine that deals with the anatomy, physiology and diseases of eye. Recent advancements in genetics and stem cell biology have brought number of changes to the Ophthalmology Therapeutics Market.
Asia-Pacific Ophthalmology Therapeutics is driven by the growing prevalence for vision impairment. According to a recent update by WHO the prevalence of visual impairment is nearly 285 million globally. Of these 246 million people have moderate to severe visual impairment. South-East Asia and Western Pacific accounted for 73% of the total visual impairments. Other major factors driving the growth of market include, increasing awareness about the importance of detecting ophthalmic diseases as early as possible and the availability of efficient diagnostic tools. However, stringent regulatory framework and lack of reimbursement policies are restraining the growth of the market.
Asia-Pacific Ophthalmology Therapeutics is broadly categorized into Indication and End User. Based on indication the market is segmented into Glaucoma, Dry Eye Syndrome, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration, Macular Edema and Allergic Conjunctivitis. Glaucoma is the largest indication segment accounting for a share of approximately XX%. On the basis of End User, the market is segmented into Hospitals, Eye Clinics, Diagnostic Centres and Patients.
Geographically, Asia-Pacific Ophthalmology therapeutics market is segmented into various regions namely China, India, Japan, South Korea and Australia. Asia-Pacific is the fastest growing region with a CAGR of xx% during the forecast period. Within Asia-Pacific, Japan is the largest market for Opthalmology therapeutics accounting for a share of approximately 45% followed by China
Pfizer Inc., Allergan Inc., Alcon Inc., Merck & co. Inc., Roche, Valeant, Regeneron, Santen, Bayer, Senju, Lpath and Eye Gate Pharmaceuticals are the major companies covered in the report.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Indication
5.1.1 Glaucoma
5.1.2 Dry Eye Syndrome
5.1.3 Diabetic Retinopathy
5.1.4 Retinal Vein Occlusion
5.1.5 Age-Related Macular Degeneration (AMD)
5.1.6 Macular Edema
5.1.7 Allergic Conjunctivitis
5.2 By End User
5.2.1 Hospitals
5.2.2 Eye Clinics
5.2.3 Diagnostic Centers
5.2.4 Patients
6. Geographical Analysis
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 Allergan, Inc.
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.2 Merck & Co Inc
9.3 Pfizer
9.4 Roche
9.5 Novartis (Alcon)
9.6 Valeant
9.7 Regeneron
9.8 Santen
9.9 Bayer
9.10 Senju
9.11 Lpath
9.12 Eye Gate Pharmaceuticals
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Market Outlook & Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
